Vertex 肾病药物因感染风险在 FDA 审批前受审视

Vertex’s drug is widely expected to secure FDA approval, but a previously undisclosed pause rule has raised questions about the drug’s label

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

This is the online version of Adam’s Biotech Scorecard, a weekly newsletter featuring exclusive, spicy analysis on the biotech industry. Sign up here to get it delivered to your inbox.

Spain is amazing. I was in Madrid for five days covering the ESMO conference. Now, I’m delivering this newsletter to you from a balcony overlooking the Mediterranean.

Vertex kidney disease drug scrutinized for infection risk ahead of FDA approval decision

So many medical meetings, so little time. While I was in Madrid reporting on cancer drugs, kidney disease specialists and the investors and analysts who tag along were in Denver for the annual meeting of the American Society of Nephrology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

1. 

   Senior Writer, Biotech

   Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.